Clinical Data (CLDA) Posts Q2 Loss of $0.79, Misses by 9c
More News related to CLDA
- Clinical Data, Inc. to Present at Piper Jaffray Health Care Conference
- Clinical Data, Inc. Initiates Phase III Trial of Stedivaze for Cardiac Stress Testing
- Clinical Data, Inc. Establishes Scientific Advisory Board for Cardiovascular Genetics
- Trading Overview for Sequenom Inc. Issued by StockPreacher.com
- Clinical Data, Inc. Launches Genetic Test for Dilated Cardiomyopathy (DCM) at the 2009 American Heart Association Meeting
More News related to Earnings
- Dow Jones, S&P 500 Close Today's Trading Session at Fresh 2009 Highs
- Sign of the Times: U.S. Mint Has To Temporarily Suspend Sales of One Ounce Gold Coins Due to Demand
- Crude Inventories Lower than Expected, Energy Shares Gain Ground (XOM, COP, CVX, MRO, USO, OIL)
- Gold Moves Higher on Weak Dollar, Lower Commodities, Indian Reserve Bank Talk (GLD, ABX, GG, NEM, GDX)
- Novartis (NVS) Excites Incyte (INCY) with Licensing Deal
Clinical Data, Inc. (NASDAQ: CLDA) reports Q2 loss of $0.79, versus the analyst estimate of ($0.70). Revenue for the quarter was $3.70 million, which compares to the estimate of $3.90 million.
Related Categories
EarningsStocks Mentioned
+0.15Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
